摘要
目的观察对颈椎间盘突出症患者在药物治疗基础上联合射频消融术干预的临床效果。方法取2018年收治颈椎间盘突出症患者群体数据为本次研究对象,有96例,将其进行数字编序并以随机分配方式分为对照组与观察组,各组有48例,对应接受射频消融术治疗、联合药物治疗。比较两组患者治疗后相关临床数据并归纳联合治疗方案对颈椎间盘突出症的临床干预效果。结果在治疗后观察组患者TNF-α(血清肿瘤坏死因子)、IL-1(白细胞介素-1)、IL-6(白细胞介素-6)以及P-P38MAPK(磷酸化-38丝裂元活化蛋白激酶)等指标检测所得数据显著优于对照组(P<0.05);在治疗后观察组患者颈椎病症量表评价所得数据均显著优于对照组(P<0.05)。结论对颈椎间盘突出症患者在拟定治疗方案的时候选择射频消融术联合药物治疗能够对患者的血清炎性介质以及通路蛋白指标有效改善,值得推广。
Objective To observe the clinical effect of radiofrequency ablation on the basis of drug therapy in patients with cervical disc herniation.Methods The data of patients with cervical disc herniation were collected in 2018.There were 96 cases,which were digitally sequenced and divided into control group and observation group by random allocation.There were 48 cases in each group,corresponding to receive radiofrequency ablation treatment,combined with drug therapy.The clinical data of the two groups were compared and the clinical intervention effect of the combined treatment regimen on cervical disc herniation was summarized.Results After treatment,TNF-α(serum tumor necrosis factor),IL-1(interleukin-1),IL-6(interleukin-6)and P-P38MAPK(phosphorylation-38 mitosis)in the observation group were significantly better than those in the control group(P<0.05).After treatment,the evaluation data of cervical syndrome scale in the observation group were significantly better than that in the control group(P<0.05).Conclusion The choice of radiofrequency ablation combined with drug therapy in patients with cervical disc herniation can effectively improve serum inflammatory mediators and pathway protein markers in patients with cervical disc herniation,which is worth popularizing.
作者
曹成哲
CAO Cheng-zhe(General Hospital of China Sinohydro Bureau Co.,LTD,Jilin,Jilin 132200)
出处
《智慧健康》
2019年第32期173-174,共2页
Smart Healthcare
关键词
颈椎间盘突出症
射频消融术
药物治疗
Cervical disc herniation
Radiofrequency ablation
Drug therapy
